MGF

MGF (Mechano Growth Factor) is an alternative splice variant of the IGF-1 gene, designated IGF-1Ec in humans and IGF-1Eb in rodents, expressed locally in skeletal muscle in response to mechanical loading or damage. Rather than the systemic IGF-1Ea isoform, mechanically stressed muscle transiently splices toward the MGF transcript at the site of injury, making it one of the earliest signals in the repair cascade.

Structurally, MGF is distinguished by a 49 base pair insert that shifts the reading frame and yields a 24 amino acid C-terminal E-domain peptide absent from mature IGF-1. This E-domain is the basis for the commercially synthesised peptide and is held to account for biological activity distinct from classical IGF-1 receptor signalling.

The synthetic product is a research compound, not FDA approved for human use. It is a WADA prohibited substance under peptide hormones and growth factors, and is banned by the UFC, NFL, NCAA, NHL, MLB, NAIA and PGA.

The defining pharmacokinetic constraint is a half-life of approximately 5 to 7 minutes. Endogenous MGF acts in an autocrine and paracrine fashion at the site of damage and therefore has no requirement for circulatory persistence; exogenous MGF degrades before meaningful systemic distribution. This constraint dictates the entire administration strategy and is the principal reason PEG-MGF, the pegylated analogue, is often preferred.

Muscle responds to mechanical damage in two sequential phases, and MGF governs the first.

Mechanical overload triggers a rapid pulse of MGF expression at the damaged site within hours. Its primary role is satellite cell activation. Satellite cells are quiescent myogenic stem cells residing between the sarcolemma and basal lamina. MGF drives their exit from quiescence and subsequent proliferation; the expanded pool later donates myonuclei to damaged fibres, raising the myonuclear domain capacity for protein synthesis and permitting hypertrophy.

The MGF E-domain peptide signals independently of the IGF-1 receptor. Published work shows activation of ERK1/2 (extracellular signal-regulated kinase) signalling without the Akt pathway activation characteristic of mature IGF-1, indicating divergent downstream biology despite common gene origin.

Phase two involves a shift to IGF-1Ea, the systemic isoform, which promotes differentiation and fusion of the activated satellite cell pool with existing fibres. MGF initiates and expands the repair population; IGF-1Ea directs maturation. The phases are sequential rather than concurrent.

The operative limitation is the 5 to 7 minute half-life. Endogenous MGF acts in situ; exogenous peptide is cleared before appreciable distribution to distant tissue. Subcutaneous abdominal administration, adequate for most peptides, is pharmacokinetically inappropriate here. Intramuscular delivery into the just-trained muscle is required to place the peptide at the satellite cell niche before degradation.

MGF expression in response to exercise declines with age, paralleling the fall in circulating growth hormone. Elderly subjects show impaired capacity to upregulate MGF after loading, a plausible contributor to sarcopenia. Administration of growth hormone alongside resistance exercise in older adults significantly enhanced MGF mRNA levels, positioning growth hormone as a principal regulator of muscle MGF expression.

The primary and best-supported action is satellite cell activation and the downstream repair cascade. Human muscle cell culture work showed MGF-E peptide significantly increased the proliferative lifespan of satellite cells from neonatal and young adult muscle and delayed senescence in those populations.

Action is local rather than systemic, which underpins intramuscular delivery into the trained muscle. Intramuscular injection of MGF cDNA in animal models produced a 25% increase in mean muscle fibre cross-sectional area within three weeks.

Neuroprotection is a distinct and reasonably consistent finding. In gerbil brain ischemia models the synthetic MGF C-terminal peptide conferred significant protection to vulnerable neurons, equivalent to but longer lasting than full-length IGF-1, and operating independently of the IGF-1 receptor. MGF overexpression also increased neural progenitor cells in the hippocampus and subventricular zone of ageing mice and preserved olfactory function when induced early.

Cardioprotection has been demonstrated in large and small animal models. MGF E-domain treatment after myocardial infarction in sheep preserved cardiac function with 35% less compromised myocardium than controls; murine follow-up work attributed this to prevention of mitochondrial membrane collapse and inhibition of caspase-3 activation, blocking the apoptotic pathway in stressed cardiomyocytes.

A 2023 review reported high MGF expression in chondrocytes, particularly in cartilage damaged by trauma or degenerative disease such as osteoarthritis, where it transduces mechanical stimuli, regulates chondrocyte activity and contributes to cartilage homeostasis, influencing proliferation, migration, differentiation, inflammatory responses and apoptosis.

Countervailing evidence exists: replication attempts found no proliferative effect of MGF peptide up to 500 ng/mL on C2C12 cells, primary human myoblasts or primary mouse muscle stem cells, and synthetic E-domain peptides alone produced no IGF-1 receptor activation at any concentration tested.

No published human clinical trial data exists for synthetic MGF injection protocols targeting muscle growth or recovery. Available evidence is in vitro, animal gene-delivery based, or anecdotal.

The 5 to 7 minute half-life dominates the practical picture. Rapid degradation in circulation means intramuscular administration into the target tissue is the only route with a plausible chance of delivering peptide to the satellite cell niche before clearance.

Among users reporting benefit, the pattern is subtle improvement in recovery speed for injected muscle groups across 4 to 6 weeks, with reduced DOMS the most frequently cited outcome. A smaller subset reports visible improvement in lagging body parts over 4 to 6 week cycles with consistent post-training intramuscular administration.

Reports on standard, non-pegylated MGF are mixed, and a significant proportion describe minimal or no perceptible effect. The recurring complaint is that the protocol's demands — immediate post-workout intramuscular injection into the trained muscle, a very narrow timing window — are not repaid by the magnitude of the result. Many users migrate to PEG-MGF for the extended active window and simpler schedule despite its thinner published evidence base.

The scientific picture reinforces this uncertainty. Foundational work supports MGF's role in the endogenous repair process, but replication failures with the synthetic E-domain peptide and the absence of confirmed IGF-1 receptor activation mean it remains unclear whether injecting the peptide reproduces those effects.

Commonly reported side effects are injection site pain, redness and swelling, headaches and temporary water retention. Less commonly, mild hypoglycaemia, particularly on low carbohydrate intake, plus fatigue and joint discomfort.

No published dose-finding studies exist for subcutaneous or intramuscular synthetic MGF peptide. Animal research used intramuscular MGF cDNA gene delivery rather than peptide injection, complicating translation, and in vitro work tested synthetic MGF E-peptide at 50 to 500 ng/mL on cell cultures. The protocol below represents clinical practice patterns rather than trial-derived dosing.

Standard protocol: 200 to 400 mcg per injection, 2 to 3 times per week on training days only, administered intramuscularly into the trained muscle group immediately post-workout and within 15 minutes of finishing. Cycle length 4 to 6 weeks. Maximum weekly dose 2 mg.

A representative week: Monday, chest training followed by 200 to 400 mcg IM into the chest; Wednesday, back training followed by 200 to 400 mcg IM into the lats; Friday, leg training followed by 200 to 400 mcg IM into the quads.

Reconstitution: 2 mg vial with 1 mL bacteriostatic water, yielding 200 mcg per 10 units on an insulin syringe.

Route is dictated by pharmacokinetics, not preference. The 5 to 7 minute half-life requires the peptide to reach target tissue before degradation. Subcutaneous abdominal administration after a lower-body session will not deliver meaningful concentrations to the quadriceps, since clearance precedes distribution. Subcutaneous injection is technically possible but unlikely to be effective.

Cycling at 4 to 6 weeks rests on the rationale of preventing receptor desensitisation, analogous to IGF-1 LR3 practice, and is not supported or refuted by published data. The mechanism of satellite cell activation applies regardless of sex, and published research has used both male and female tissue; no sex-specific safety concerns appear in the literature beyond the standard contraindications. Glucocorticoid treatment may inhibit the growth-promoting effects of MGF, and caution is warranted alongside insulin or other blood glucose medication given IGF-1 family insulin-like activity.

The foundational work is Hill and Goldspink (2003, J Physiol), which established that IGF-1 gene splicing in damaged rodent muscle yields a rapid MGF pulse responsible for satellite cell activation, with IGF-1Ea upregulation following to drive differentiation. Goldspink (2005, Physiology) extended this to mechanically overloaded muscle, tissue repair, and impaired MGF expression capacity in the elderly.

Kandalla et al. (2011, Mech Ageing Dev) applied MGF-24aa-E peptide to human primary muscle cell cultures across ages, reporting increased proliferative lifespan, delayed senescence and greater fusion potential in neonatal and young adult satellite cells, with attenuated effects in older donors. The authors framed MGF as a possible sarcopenia strategy without the oncogenic concerns attached to full-length IGF-1. This was in vitro, not in vivo.

Non-muscle findings are consistent across models. Dluzniewska et al. (2005, FASEB J) reported strong neuroprotection from the synthetic C-terminal peptide in gerbil brain ischaemia, equivalent to but longer lasting than full-length IGF-1 and independent of the IGF-1 receptor. Tang et al. (2017, Mol Brain) showed MGF overexpression raised neural progenitor numbers and promoted neurogenesis in the ageing mouse brain with preserved olfactory function when induced early. Carpenter et al. (2008, Heart Lung Circ) found 35% less compromised cardiac muscle in a sheep infarct model; Mavrommatis et al. (2013, Mol Cell Biochem) attributed this to prevention of mitochondrial membrane collapse and inhibition of caspase-3 activation. Liu et al. (2023) reviewed high MGF expression in chondrocytes of damaged cartilage.

The counter-evidence is substantial. Fornaro et al. (2014, Am J Physiol Endocrinol Metab), from two pharmaceutical companies, found MGF peptide up to 500 ng/mL failed to increase proliferation in C2C12 cells, primary human myoblasts or primary mouse muscle stem cells, while mature IGF-1 did in all three. Janssen et al. (2016, PLOS ONE) found full-length MGF could activate the IGF-1 receptor at high concentrations but synthetic E-domain peptides alone produced no receptor activation at any concentration. Matheny et al. (2010) and Zablocka et al. (2012) both note that no analogous endogenous E-peptide product has been conclusively identified. Any activity of the commercial peptide likely runs through an ERK1/2-linked route that is not yet fully characterised. No published human dose-finding or efficacy trial exists.